Kamada (KMDA)
Develops plasma-derived therapies and distributes biopharmaceutical products in Israel and the MENA region.
$8.75
vs last close−0.12 (−1.35%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38 | 36 | 38 | 42 | 42 | 39 | 44 | 45 | 47 | 45 | 45 | 55 |
| Cost of revenue | 23 | 22 | 21 | 24 | 25 | 22 | 23 | 26 | 27 | 28 | 26 | 32 |
| Gross profit | 15 | 14 | 17 | 19 | 17 | 17 | 21 | 19 | 20 | 17 | 19 | 22 |
| 10 | 12 | 13 | 13 | 12 | 12 | 13 | 12 | 12 | 13 | 12 | 13 | |
| Research & development | 3 | 3 | 4 | 5 | 3 | 3 | 4 | 3 | 3 | 3 | 2 | 2 |
| 7 | 5 | 8 | 9 | 9 | 5 | 9 | 9 | 9 | 7 | 10 | 11 | |
| Selling & marketing | 4 | −2 | 5 | 5 | 5 | −3 | 5 | 5 | 5 | −4 | 5 | 5 |
| General & administrative | 4 | 8 | 4 | 4 | 4 | 9 | 4 | 4 | 5 | 11 | 5 | 6 |
| Other expenses | 0 | 3 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 3 | 0 | 0 |
| Operating income | 4 | 3 | 4 | 6 | 5 | 5 | 8 | 7 | 8 | 4 | 7 | 10 |
| −1 | 2 | −2 | −1 | −1 | −3 | −1 | −1 | −1 | 1 | −2 | 1 | |
| Interest income | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 1 | −2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | −1 | 1 | 0 |
| Income before tax | 3 | 5 | 2 | 4 | 4 | 2 | 7 | 6 | 6 | 5 | 5 | 10 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | −1 | 3 | −2 | 1 | 1 | 1 | 1 |
| Net income from continuing operations | 3 | 5 | 2 | 4 | 4 | 4 | 4 | 7 | 5 | 4 | 4 | 9 |
| Net income | 3 | 5 | 2 | 4 | 4 | 4 | 4 | 7 | 5 | 4 | 4 | 9 |
| EPS, basic | $0.07 | $0.09 | $0.04 | $0.08 | $0.07 | $0.07 | $0.07 | $0.13 | $0.09 | $0.06 | $0.07 | $0.16 |
| EPS, diluted | $0.06 | $0.09 | $0.04 | $0.08 | $0.07 | $0.07 | $0.07 | $0.13 | $0.09 | $0.06 | $0.07 | $0.16 |
| Weighted average shares, basic | 46 | 57 | 57 | 55 | 55 | 54 | 57 | 57 | 59 | 58 | 59 | 58 |
| Weighted average shares, diluted | 54 | 57 | 57 | 55 | 55 | 54 | 57 | 57 | 59 | 62 | 59 | 58 |
| EBITDA | 7 | 8 | 6 | 8 | 7 | 7 | 10 | 10 | 10 | 9 | 9 | 13 |
| Depreciation & amortization | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EBIT | 4 | 5 | 3 | 5 | 4 | 3 | 7 | 6 | 7 | 5 | 6 | 10 |